Roca Therapeutics, a Nice, France-based biotech startup, raised an undisclosed amount of funding.
The round was led by BPI, with participation form PACA Cancéropôle, UCA, Eurobiomed Grand Sud and Southern Regional council.
The company intends to use the funds to develop its Lead Clinical candidate RCT001 (Metastatic Uveal Melanoma) until IND/CTA readiness in 2023, and to further expand the company’s portfolio of assets with the nomination of a second clinical candidate against Neovascular Glaucoma associated to Uveal melanoma.
Led by CEO Dr. Maeva Dufies, Roca Therapeutics is a biotechnology company that designs small molecules addressing dedicated pathobiological mechanisms (M2 Macrophages driven immunosuppression and resistant angiogenesis) recently linked to indications such as Uveal Melanoma as well as Renal Cell Carcinoma and Head and Neck Squamous Cell Carcinoma.
FinSMEs
26/09/2022